Navigation Links
OncoSec Medical Reports Third Quarter 2011 Financial Results
Date:6/15/2011

for the comparable three and nine month periods was due to an increase in salary, legal and other expenses associated with the increase in operations stemming from our shift in focus to the biomedical industry.

Net Loss Attributable to Common Stockholders

The $491,000 increase in net loss attributable to common stockholders for the nine months ended April 30, 2011, compared with the same period in 2010, resulted from our shift in focus to be a biomedical company concentrated on developing cancer therapeutic products.

Capital Resources

As of April 30, 2011, our cash balance was $543,000, compared to $237 as of July 31, 2010. This change primarily resulted from an increase in cash resulting from proceeds of $1,092,000 we received in connection with a private placement of common stock announced on March 18, 2011. This was offset by the initial scheduled payment of $250,000 made to Inovio during March 2011, in accordance with the Asset Purchase Agreement, and operating expenses incurred during the nine month period ended April 30, 2011. With this private placement, we issued 1,456,000 units at a purchase price of $0.75 per unit for gross proceeds of $1,092,000. Each unit consisted of one share of common stock and one share purchase warrant entitling the holder to acquire one share of common stock at a price of $1.00 per share for a period of five years from the closing of the private placement.

Stockholders Equity (Deficit)

As of April 30, 2011, we had a stockholder's equity balance of $556,000 compared to a deficit balance of $30,000 at July 31, 2010, and also had 52,656,000 and 68,480,000 shares of common stock issued and outstanding for the same respective periods.

Corporate Update

Corporate Development

In this quarter, OncoSec purchased certain non-DNA vaccine technology and intellectual property from Inovio relating to electroporation delivery of chemotherape
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoSec Medical Appoints Punit Dhillon as President and CEO
2. OncoSec Medical Featured in Medical Device Daily
3. OncoSec Announces Leadership Team Appointments
4. OncoSec Announces Clinical Leadership Appointments
5. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
6. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
7. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
8. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
9. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
10. BioMS Medical Announces Second Quarter 2008 Results
11. ATS Medical to Participate at the Fourth Annual Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Telegraph and Telephone Corp. is opening a liason office ... of Wisconsin-Platteville campus. Hiroki Tanaka, vice president and general ... responsible for seeking out opportunities for the company to ... began their relationship during governor Jim Doyle's trade mission ...
... is about the only card American businesses have left ... threat posed by China, and chief information officers must ... and business innovator Tom Peters. , ,Peters spoke on ... to a gathering of Wisconsin business executives during the ...
... Milwaukee, Wis. Neurognostics Inc. said it has ... a combined functional magnetic resonance imaging software product. , ... clinical practice," said Doug Tucker, CEO of Neurognostics ... to collaborate on our efforts to develop clinically useful ...
Cached Biology Technology:Peters: Innovation the only edge that remains for American business 2
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... at Case Western Reserve School of Medicine have discovered ... type of brain cells destroyed in patients with multiple ... This discovery appears today in the journal ... "on demand" production of myelinating cells, which provide a ...
... blocked bowel arteries, preventing damage and even death ... and leads to excessive weight loss, notes research ... 38th Annual Scientific Meeting in New Orleans, La. ... said Daniel A. Leung, M.D., program director of ...
... causes a slime to form, making bacteria hard to ... some bacteria can shield themselves in a slimy protective ... of communities of bacteria held together to protect themselves ... in healthcare, biofilms can lead to life threatening and ...
Cached Biology News:Ordinary skin cells morphed into functional brain cells 2Stenting blocked bowel arteries saves lives 2Secrets of bacterial slime revealed 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: